Cargando…

Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort

BACKGROUND: The effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals have been discordant. We assessed the impact of statin-based primary prevention on all-cause mortality a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lang, Sylvie, Lacombe, Jean-Marc, Mary-Krause, Murielle, Partisani, Marialuisa, Bidegain, Frédéric, Cotte, Laurent, Aslangul, Elisabeth, Chéret, Antoine, Boccara, Franck, Meynard, Jean-Luc, Pradier, Christian, Roger, Pierre-Marie, Tattevin, Pierre, Costagliola, Dominique, Molina, Jean-Michel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511794/
https://www.ncbi.nlm.nih.gov/pubmed/26200661
http://dx.doi.org/10.1371/journal.pone.0133358
_version_ 1782382398002954240
author Lang, Sylvie
Lacombe, Jean-Marc
Mary-Krause, Murielle
Partisani, Marialuisa
Bidegain, Frédéric
Cotte, Laurent
Aslangul, Elisabeth
Chéret, Antoine
Boccara, Franck
Meynard, Jean-Luc
Pradier, Christian
Roger, Pierre-Marie
Tattevin, Pierre
Costagliola, Dominique
Molina, Jean-Michel
author_facet Lang, Sylvie
Lacombe, Jean-Marc
Mary-Krause, Murielle
Partisani, Marialuisa
Bidegain, Frédéric
Cotte, Laurent
Aslangul, Elisabeth
Chéret, Antoine
Boccara, Franck
Meynard, Jean-Luc
Pradier, Christian
Roger, Pierre-Marie
Tattevin, Pierre
Costagliola, Dominique
Molina, Jean-Michel
author_sort Lang, Sylvie
collection PubMed
description BACKGROUND: The effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals have been discordant. We assessed the impact of statin-based primary prevention on all-cause mortality among HIV-infected individuals. METHODS: Patients were selected among controls from a multicentre nested case-control study on the risk of myocardial infarction. Patients with prior cardiovascular or cerebrovascular disorders were not eligible. Potential confounders, including variables that were associated either with statin use and/or death occurrence and statin use were evaluated within the last 3 months prior to inclusion in the case-control study. Using an intention to continue approach, multiple imputation of missing data, Cox’s proportional hazard models or propensity based weighting, the impact of statins on the 7-year all-cause mortality was evaluated. RESULTS: Among 1,776 HIV-infected individuals, 138 (8%) were statins users. During a median follow-up of 53 months, 76 deaths occurred, including 6 in statin users. Statin users had more cardiovascular risk factors and a lower CD4 T cell nadir than statin non-users. In univariable analysis, the death rate was higher in statins users (11% vs 7%, HR 1.22, 95%CI 0.53-2.82). The confounders accounted for were age, HIV transmission group, current CD4 T cell count, haemoglobin level, body mass index, smoking status, anti-HCV antibodies positivity, HBs antigen positivity, diabetes and hypertension. In the Cox multivariable model the estimated hazard ratio of statin on all-cause mortality was estimated as 0.86 (95%CI 0.34-2.19) and it was 0.83 (95%CI 0.51-1.35) using inverse probability treatment weights. CONCLUSION: The impact of statin for primary prevention appears similar in HIV-infected individuals and in the general population.
format Online
Article
Text
id pubmed-4511794
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-45117942015-07-24 Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort Lang, Sylvie Lacombe, Jean-Marc Mary-Krause, Murielle Partisani, Marialuisa Bidegain, Frédéric Cotte, Laurent Aslangul, Elisabeth Chéret, Antoine Boccara, Franck Meynard, Jean-Luc Pradier, Christian Roger, Pierre-Marie Tattevin, Pierre Costagliola, Dominique Molina, Jean-Michel PLoS One Research Article BACKGROUND: The effect of statins on all-cause mortality in the general population has been estimated as 0.86 (95%CI 0.79-0.94) for primary prevention. Reported values in HIV-infected individuals have been discordant. We assessed the impact of statin-based primary prevention on all-cause mortality among HIV-infected individuals. METHODS: Patients were selected among controls from a multicentre nested case-control study on the risk of myocardial infarction. Patients with prior cardiovascular or cerebrovascular disorders were not eligible. Potential confounders, including variables that were associated either with statin use and/or death occurrence and statin use were evaluated within the last 3 months prior to inclusion in the case-control study. Using an intention to continue approach, multiple imputation of missing data, Cox’s proportional hazard models or propensity based weighting, the impact of statins on the 7-year all-cause mortality was evaluated. RESULTS: Among 1,776 HIV-infected individuals, 138 (8%) were statins users. During a median follow-up of 53 months, 76 deaths occurred, including 6 in statin users. Statin users had more cardiovascular risk factors and a lower CD4 T cell nadir than statin non-users. In univariable analysis, the death rate was higher in statins users (11% vs 7%, HR 1.22, 95%CI 0.53-2.82). The confounders accounted for were age, HIV transmission group, current CD4 T cell count, haemoglobin level, body mass index, smoking status, anti-HCV antibodies positivity, HBs antigen positivity, diabetes and hypertension. In the Cox multivariable model the estimated hazard ratio of statin on all-cause mortality was estimated as 0.86 (95%CI 0.34-2.19) and it was 0.83 (95%CI 0.51-1.35) using inverse probability treatment weights. CONCLUSION: The impact of statin for primary prevention appears similar in HIV-infected individuals and in the general population. Public Library of Science 2015-07-22 /pmc/articles/PMC4511794/ /pubmed/26200661 http://dx.doi.org/10.1371/journal.pone.0133358 Text en © 2015 Lang et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Lang, Sylvie
Lacombe, Jean-Marc
Mary-Krause, Murielle
Partisani, Marialuisa
Bidegain, Frédéric
Cotte, Laurent
Aslangul, Elisabeth
Chéret, Antoine
Boccara, Franck
Meynard, Jean-Luc
Pradier, Christian
Roger, Pierre-Marie
Tattevin, Pierre
Costagliola, Dominique
Molina, Jean-Michel
Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort
title Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort
title_full Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort
title_fullStr Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort
title_full_unstemmed Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort
title_short Is Impact of Statin Therapy on All-Cause Mortality Different in HIV-Infected Individuals Compared to General Population? Results from the FHDH-ANRS CO4 Cohort
title_sort is impact of statin therapy on all-cause mortality different in hiv-infected individuals compared to general population? results from the fhdh-anrs co4 cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511794/
https://www.ncbi.nlm.nih.gov/pubmed/26200661
http://dx.doi.org/10.1371/journal.pone.0133358
work_keys_str_mv AT langsylvie isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT lacombejeanmarc isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT marykrausemurielle isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT partisanimarialuisa isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT bidegainfrederic isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT cottelaurent isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT aslangulelisabeth isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT cheretantoine isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT boccarafranck isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT meynardjeanluc isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT pradierchristian isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT rogerpierremarie isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT tattevinpierre isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT costaglioladominique isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT molinajeanmichel isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort
AT isimpactofstatintherapyonallcausemortalitydifferentinhivinfectedindividualscomparedtogeneralpopulationresultsfromthefhdhanrsco4cohort